28.28
-0.88 (-3.02%)
| Penutupan Terdahulu | 29.16 |
| Buka | 29.60 |
| Jumlah Dagangan | 30,590,202 |
| Purata Dagangan (3B) | 46,979,883 |
| Modal Pasaran | 66,718,990,336 |
| Harga / Pendapatan (P/E TTM) | 27.19 |
| Harga / Pendapatan (P/E Ke hadapan) | 25.58 |
| Harga / Jualan (P/S) | 7.58 |
| Harga / Buku (P/B) | 4.02 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 20 Aug 2025 - 25 Aug 2025 |
| Hasil Dividen (DY TTM) | 0.82% |
| Margin Keuntungan | 22.95% |
| Margin Operasi (TTM) | 23.60% |
| EPS Cair (TTM) | 0.930 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 17.00% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 75.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 19.71% |
| Nisbah Semasa (MRQ) | 1.71 |
| Aliran Tunai Operasi (OCF TTM) | 3.20 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 1.54 B |
| Pulangan Atas Aset (ROA TTM) | 6.82% |
| Pulangan Atas Ekuiti (ROE TTM) | 12.84% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (HK) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | 3SBIO | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.25 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| 3SBIO | 67 B | 0.82% | 27.19 | 4.02 |
| KEYMED BIO-B | 19 B | - | - | 4.95 |
| ASCLETIS-B | 14 B | - | - | 6.56 |
| HAOHAI BIOTEC | 12 B | 3.41% | 14.58 | 1.00 |
| AKESO | 111 B | - | - | 15.36 |
| PHARMARON | 56 B | 0.92% | 22.04 | 2.34 |
|
3SBio Inc is a biotechnology company. As a pioneer in the Chinese biotechnology industry, the Group has extensive expertise in researching, developing, manufacturing, and marketing biopharmaceuticals. The core products of the Group include several biopharmaceutical drugs, TPIAO recombinant human erythropoietin rhEPO products EPIAO and SEPO, Yisaipu, Cipterbin, and a small molecule drug, Mandi. Except for minoxidil, an over-the-counter drug, the others are all older-generation biologics. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Value |
| % Dimiliki oleh Orang Dalam | 27.05% |
| % Dimiliki oleh Institusi | 23.31% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |